Figure 6.

RNASE4 mediates oncogenic effects and cIAPs induction by HIF1A in U87MG cells. (A) Effects of HIF1A overexpression on RNASE4, cIAP1, cIAP2, and SURVIVIN protein levels in U87MG cells were assessed by Western blot analysis. (B) Transwell migration assays and oncosphere formation assays (C) were conducted to evaluate changes in cell motility and cancer stemness following HIF1A overexpression in U87MG cells. The right panel displays the statistical quantification results (**P<0.01). (D) The effects of RNASE4 knockdown on the expression levels of cIAP1, cIAP2, and SURVIVIN in HIF1A-overexpressing U87MG cells were assessed by Western blot analysis. (E, F) The effects of RNASE4 knockdown on the migration and oncosphere formation capacities of HIF1A-overexpressing U87MG cells were evaluated using transwell migration and oncosphere formation assays. Data are presented as mean ± SEM from three independent experiments (**P<0.01). (G) MTS assay was conducted to evaluate the effects of LCL-161 (cIAP1/2 inhibitor, 10 µM) and YM-155 (SURVIVIN inhibitor, 5 nM) on control and RNASE4-overexpressing U87MG cells treated with Temozolomide (TMZ) for 3 days (*P<0.05, **P<0.01).